NasdaqGS:VRTXBiotechs
Assessing Vertex Pharmaceuticals (VRTX) Valuation After ALYFTREK Expansion And Supportive Bank Of America Commentary
Vertex Pharmaceuticals (VRTX) is back in focus after the US Food and Drug Administration approved expanded use of ALYFTREK for cystic fibrosis patients aged 6 and older, alongside supportive commentary from Bank of America on its core franchises.
See our latest analysis for Vertex Pharmaceuticals.
Despite the positive ALYFTREK decision and supportive commentary from Bank of America, the share price has seen a 10.19% decline over 90 days and a 6.24% year to date share price return. The 5 year...